Charles River Laboratories International, Inc. (NYSE:CRL) Shares Sold by Wrapmanager Inc.

Wrapmanager Inc. cut its position in Charles River Laboratories International, Inc. (NYSE:CRL) by 11.6% during the 2nd quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 1,307 shares of the medical research company’s stock after selling 172 shares during the quarter. Wrapmanager Inc.’s holdings in Charles River Laboratories International were worth $270,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also recently bought and sold shares of CRL. Tortoise Investment Management LLC raised its holdings in shares of Charles River Laboratories International by 77.0% during the second quarter. Tortoise Investment Management LLC now owns 131 shares of the medical research company’s stock valued at $27,000 after buying an additional 57 shares during the last quarter. Headlands Technologies LLC bought a new stake in Charles River Laboratories International during the 1st quarter valued at $41,000. Brown Brothers Harriman & Co. boosted its position in Charles River Laboratories International by 76.0% during the 4th quarter. Brown Brothers Harriman & Co. now owns 220 shares of the medical research company’s stock worth $52,000 after acquiring an additional 95 shares during the period. Whittier Trust Co. of Nevada Inc. grew its stake in shares of Charles River Laboratories International by 219.3% in the second quarter. Whittier Trust Co. of Nevada Inc. now owns 281 shares of the medical research company’s stock worth $58,000 after purchasing an additional 193 shares in the last quarter. Finally, Concord Wealth Partners increased its holdings in shares of Charles River Laboratories International by 362.5% during the first quarter. Concord Wealth Partners now owns 259 shares of the medical research company’s stock valued at $70,000 after purchasing an additional 203 shares during the period. 98.91% of the stock is owned by institutional investors and hedge funds.

Analyst Ratings Changes

A number of equities analysts recently issued reports on CRL shares. TD Cowen decreased their target price on shares of Charles River Laboratories International from $228.00 to $203.00 and set a “hold” rating for the company in a research report on Monday, August 12th. JPMorgan Chase & Co. lowered shares of Charles River Laboratories International from an “overweight” rating to a “neutral” rating and lowered their price objective for the company from $270.00 to $205.00 in a research note on Thursday, August 8th. Baird R W downgraded Charles River Laboratories International from a “strong-buy” rating to a “hold” rating in a research report on Thursday, August 8th. StockNews.com upgraded Charles River Laboratories International from a “hold” rating to a “buy” rating in a research report on Tuesday, August 20th. Finally, Argus restated a “hold” rating on shares of Charles River Laboratories International in a report on Friday, June 28th. Ten analysts have rated the stock with a hold rating and five have assigned a buy rating to the stock. According to data from MarketBeat, Charles River Laboratories International currently has an average rating of “Hold” and a consensus price target of $231.00.

Charles River Laboratories International Stock Up 2.2 %

CRL stock opened at $198.61 on Friday. The company’s 50 day simple moving average is $209.40 and its 200-day simple moving average is $225.65. Charles River Laboratories International, Inc. has a 52-week low of $161.65 and a 52-week high of $275.00. The company has a debt-to-equity ratio of 0.65, a current ratio of 1.58 and a quick ratio of 1.21. The firm has a market capitalization of $10.23 billion, a P/E ratio of 23.37, a P/E/G ratio of 3.89 and a beta of 1.36.

Charles River Laboratories International (NYSE:CRL) last announced its earnings results on Wednesday, August 7th. The medical research company reported $2.80 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.39 by $0.41. The company had revenue of $1.03 billion for the quarter, compared to the consensus estimate of $1.03 billion. Charles River Laboratories International had a net margin of 10.83% and a return on equity of 14.96%. As a group, equities research analysts anticipate that Charles River Laboratories International, Inc. will post 10.01 EPS for the current year.

Charles River Laboratories International declared that its board has authorized a stock buyback plan on Wednesday, August 7th that allows the company to buyback $1.00 billion in outstanding shares. This buyback authorization allows the medical research company to reacquire up to 9.6% of its shares through open market purchases. Shares buyback plans are generally an indication that the company’s board of directors believes its stock is undervalued.

Charles River Laboratories International Company Profile

Charles River Laboratories International, Inc provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing).